CO-ADMINISTRATION OF DORIBAX WITH VALPROIC ACID CAUSES THE SERUM CONCENTRATIONS OF VALPROIC ACID TO FALL BELOW THE THERAPEUTIC RANGE, INCREASING THE RISK FOR BREAKTHROUGH SEIZURES. PROBENECID INTERFERES WITH THE ACTIVE TUBULAR SECRETION OF DORIPENEM, RESULTING IN INCREASED PLASMA CONCENTRATIONS OF DORIPENEM.